AstraZeneca PLC (AZNCF)
OTCMKTS
· Delayed Price · Currency is USD
142.75
-2.88 (-1.97%)
Jun 5, 2025, 3:39 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
54.98B
Revenue Growth
+15.48%
P/S Ratio
4.10
Revenue / Employee
583.05K
Employees
94,300
Market Cap
225.55B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
AstraZeneca News
- 2 days ago - Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO - CNBC
- 3 days ago - AstraZeneca says Enhertu, Perjeta combo cuts death risk in breast cancer - Seeking Alpha
- 3 days ago - AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment - CNBC
- 3 days ago - How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma - Investor's Business Daily
- 3 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial - Benzinga
- 3 days ago - ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial - Benzinga
- 3 days ago - Experimental AstraZeneca pill helps cut risk of breast cancer progression - CNBC
- 4 days ago - Notable healthcare headlines for the week: AstraZeneca, Eli Lilly, Bristol Myers in focus - Seeking Alpha